Tech Company Financing Transactions
Disc Medicine Funding Round
Novo Ventures, Access Industries and Atlas Venture participated in a $50 million Series A capital raise for Disc Medicine. The funding round was announced on 10/31/2019.
Transaction Overview
Company Name
Announced On
10/31/2019
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
150 Cambridgepark Dr. 103
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Undisclosed
Website
Email Address
Overview
Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis). Focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is advancing first-in-class therapies to transform the treatment of hematologic disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Quisel
Chief Financial Officer
Joanne Bryce
Chief Medical Officer
William Savage
Vice President
Srikanth Venkatraman
Vice President
Hua Yang
VP - Bus. Development
Jonathan Yu
VP - Regulatory Affairs
Sarah Tuller
Browse more venture capital transactions:
Prev: 10/31/2019: Techtonic venture capital transaction
Next: 10/31/2019: Particle venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs